Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.

MLA

Berezhnoy, Alexey, et al. “Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.” Cell Reports. Medicine, vol. 1, no. 9, Dec. 2020, p. 100163. EBSCOhost, https://doi.org/10.1016/j.xcrm.2020.100163.

APA

Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., Cote, G. M., Luke, J. J., Sanborn, R. E., Sharma, M. R., Chen, F., Li, H., Diedrich, G., Bonvini, E., & Moore, P. A. (2020). Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Reports. Medicine, 1(9), 100163. https://doi.org/10.1016/j.xcrm.2020.100163

Chicago

Berezhnoy, Alexey, Bradley J Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu, Jonathan Li, Su-Shin Hao, et al. 2020. “Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.” Cell Reports. Medicine 1 (9): 100163. doi:10.1016/j.xcrm.2020.100163.